Warning: Undefined variable $post in /home/ksk9ball/keisyuke-ebm-summary.com/public_html/wp-content/themes/sango-theme-poripu/functions.php on line 12

Warning: Attempt to read property "ID" on null in /home/ksk9ball/keisyuke-ebm-summary.com/public_html/wp-content/themes/sango-theme-poripu/functions.php on line 12

COVID-19でヒドロキシクロロキンの使用と院内死亡率に関連はありますか? PMID:32392282


Rosenberg ES, Dufort EM, Udo T, et al.

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. 

JAMA. Published online May 11, 2020. doi:10.1001/jama.2020.8630



Key Points

Question. コロナウイルス疾患2019(COVID-19)患者のうち、アジスロマイシンの有無にかかわらず、ヒドロキシクロロキンの使用と院内死亡率との関連はあるか?

Findings. ニューヨーク大都市圏に入院した1438人の患者を対象としたレトロスペクティブコホート研究において、両薬を併用した場合と比較して、ヒドロキシクロロキン単独での治療での院内死亡率の調整後ハザード比は1.08、アジスロマイシン単独では0.56、ヒドロキシクロロキンとアジスロマイシンの併用では1.35であった。これらのハザード比はいずれも統計的に有意ではなかった。

Meaning. COVID-19で入院した患者において、ヒドロキシクロロキン、アジスロマイシン、またはその両方による治療は、院内死亡率の有意な低下とは関連していなかった。










Main Outcomes and Measures



COVID-19と診断された入院患者1438人(858人[59.7%]男性、年齢中央値63歳)のうち、ヒドロキシクロロキン、アジスロマイシン、またはその両方を投与された患者は、いずれの薬剤も投与されていない患者と比較して、糖尿病、呼吸数22/分以上、胸部画像所見異常、O2飽和度90%未満、およびアスパラギン酸アミノトランスフェラーゼ40 U/L以上を有する可能性が高かった。院内全体の死亡率は 20.3%(95%CI、18.2%~22.4%)であった。




  1. Wang  C , Horby  PW , Hayden  FG , Gao  GF .  A novel coronavirus outbreak of global health concern.   Lancet. 2020;395(10223):470-473. doi:10.1016/S0140-6736(20)30185-9PubMedGoogle ScholarCrossref
  2. The Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 dashboard. 2020. Accessed March 24, 2020. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
  3. Rosenberg  ES , Dufort  EM , Blog  DS ,  et al.  COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State—March 2020.   Clin Infect Dis. Published online May 8, 2020. doi:10.1093/cid/ciaa549Google Scholar
  4. New York State Department of Health. COVID-19 Tracker. 2020. Accessed May 7, 2020. https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Map?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n
  5. Liu  J , Cao  R , Xu  M ,  et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.   Cell Discov. 2020;6(1):16. doi:10.1038/s41421-020-0156-0PubMedGoogle ScholarCrossref
  6. Yao  X , Ye  F , Zhang  M ,  et al.  In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).   Clin Infect Dis. 2020;ciaa237. doi:10.1093/cid/ciaa237PubMedGoogle Scholar
  7. Colson  P , Rolain  JM , Lagier  JC , Brouqui  P , Raoult  D .  Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.   Int J Antimicrob Agents. 2020;55(4):105932. doi:10.1016/j.ijantimicag.2020.105932PubMedGoogle Scholar
  8. Gautret  P , Lagier  JC , Parola  P ,  et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.   Int J Antimicrob Agents. 2020:105949. doi:10.1016/j.ijantimicag.2020.105949PubMedGoogle Scholar
  9. Chen  Z , Hu  J , Zhang  Z ,  et al Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. Preprint posted April 10, 2020. doi:10.1101/2020.03.22.20040758
  10. McGhie  TK , Harvey  P , Su  J , Anderson  N , Tomlinson  G , Touma  Z .  Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus.   Clin Exp Rheumatol. 2018;36(4):545-551.PubMedGoogle Scholar
  11. Hung  YM , Wang  YH , Lin  L , Wang  PYP , Chiou  JY , Wei  JC .  Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study.   Int J Clin Pract. 2018;72(5):e13095. doi:10.1111/ijcp.13095PubMedGoogle Scholar
  12. Chorin  E , Dai  M , Shulman  E ,  et al.  The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.   Nat Med. Published online April 24, 2020. doi:10.1038/s41591-020-0888-2Google Scholar
  13. Borba  MGS , Val  FFA , Sampaio  VS ,  et al  Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial.   JAMA Netw Open. 2020;3(4):e208857. doi:10.1001/jamanetworkopen.2020.8857
  14. ArticleGoogle Scholar14.FDA. Fact sheet for health care providers: emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. Posted April 27, 2020. Accessed May 7, 2020. https://www.fda.gov/media/136537/download
  15. Garg  S , Kim  L , Whitaker  M ,  et al.  Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 States, March 1-30, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464. doi:10.15585/mmwr.mm6915e3PubMedGoogle ScholarCrossref
  16. CDC COVID-19 Response Team.  Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12-March 28, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(13):382-386. doi:10.15585/mmwr.mm6913e2PubMedGoogle ScholarCrossref
  17. Magagnoli  J , Narendran  S , Pereira  F ,  et al Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. Preprint posted April 23, 2020. doi:10.1101/2020.04.16.20065920
  18. Goyal  P , Choi  JJ , Pinheiro  LC ,  et al.  Clinical characteristics of Covid-19 in New York City.   N Engl J Med. Published online April 17, 2020. doi:10.1056/NEJMc2010419PubMedGoogle Scholar
  19. Petrilli  CM , Jones  SA , Yang  J ,  et al Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv. Preprint posted April 11, 2020. doi:10.1101/2020.04.08.20057794
  20. Davis  CE , Hyde  JE , Bangdiwala  SI , Nelson  JJ . An example of dependencies among variables in a conditional logistic regression. In: Modern Statistical Methods in Chronic Disease Epidemiology. John Wiley & Sons; 1986:140-147.
  21. Lin  DY , Wei  LJ .  The Robust inference for the Cox proportional hazards model.   J Am Stat Assoc. 1989;84(408):1074-1078. doi:10.1080/01621459.1989.10478874Google ScholarCrossref
  22. VanderWeele  TJ , Ding  P .  Sensitivity analysis in observational research: introducing the E-value.   Ann Intern Med. 2017;167(4):268-274. doi:10.7326/M16-2607PubMedGoogle ScholarCrossref
  23. Mahevas  M , Tran V-T, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. Preprint posted April 14, 2020. doi:10.1101/2020.04.10.20060699
  24. Geleris  J , Sun  Y , Platt  J ,  et al.  Observational study of hydroxychloroquine in hospitalized patients with Covid-19.   N Engl J Med. Published online May 7, 2020. doi:10.1056/NEJMoa2012410PubMedGoogle Scholar
  25. Gorgels  APM , Gijsbers  C , de Vreede-Swagemakers  J , Lousberg  A , Wellens  HJJ .  Out-of-hospital cardiac arrest: the relevance of heart failure.   Eur Heart J. 2003;24(13):1204-1209. doi:10.1016/S0195-668X(03)00191-XPubMedGoogle ScholarCrossref
  26. Low  LS , Kern  KB .  Importance of coronary artery disease in sudden cardiac death.   J Am Heart Assoc. 2014;3(5):e001339. doi:10.1161/JAHA.114.001339PubMedGoogle Scholar
  27. Richardson  S , Hirsch  JS , Narasimhan  M ,  et al; and the Northwell COVID-19 Research Consortium.  Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.   JAMA. Published online April 22, 2020. doi:10.1001/jama.2020.6775 ArticlePubMedGoogle Scholar
  28. Zhou  F , Yu  T , Du  R ,  et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.   Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3PubMedGoogle ScholarCrossref
  29. Yancy  CW .  COVID-19 and African Americans.   JAMA. Published online April 15, 2020. doi:10.1001/jama.2020.6548 ArticlePubMedGoogle Scholar
  30. NIH. COVID-19 treatment guidelines. Accessed April 24, 2020. https://covid19treatmentguidelines.nih.gov/introduction/
  31. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Posted April 11, 2020. Accessed April 24, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
  32. FDA Drug Safety Communication. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Posted April 24, 2020. Accessed May 8, 2020. https://www.fda.gov/media/137250/download






このサイトはスパムを低減するために Akismet を使っています。コメントデータの処理方法の詳細はこちらをご覧ください